SARTORIUS
Sartorius, a leading international partner of biopharmaceutical research and the industry, started off fiscal 2019 with substantial double-digit growth in order intake, sales revenue and earnings. Consolidated first-quarter sales revenue rose in constant currencies by 16.8% to 435.7 million (reported: +19.4%); order intake increased 16.6% to 482.8 million euros (reported: +19.3%).
Sartorius’ underlying EBITDA1) surged 28.7% to 114.0 million euros. Its respective underlying EBITDA margin for the first three months of 2019 was 26.2% (Q1 2018: 24.3%), with a good half a percentage point of this increase resulting from the change in accounting rules2) , as expected. Relevant net profit3) for the Group climbed 30.8% to 48.6 million euros. Earnings per ordinary share were 0.71 euros (Q1 2018: 0.54 euros); earnings per preference share, 0.72 euros (Q1 2018: 0.55 euros).
“We are very pleased with our first-quarter results,” said Dr. Joachim Kreuzburg, CEO and Executive Board Chairman. “In Bioprocess Solutions, the relatively moderate prior-year comparables, high order intake in the final quarter of 2018, and the modified setup of our cell culture media business that has not yet shown its full effects on first-quarter figures all contributed to the anticipated above-average growth rates, which are expected to normalize as the year progresses. Considering the softer economic environment especially in Europe, the Lab Products & Services Division showed robust development, which was in line with our expectations. Based on the results of the first three months, we confirm our full-year targets.”
Business development in the regions
Sartorius increased its sales revenues by double digits across all three geographies. The Americas region recorded the strongest growth, closing the first quarter with a gain in revenue of 24.7% to 152.4 million euros. The Asia | Pacific region saw a 15.3% increase in sales over the first quarter of 2018, to 105.3 million euros. In the EMEA region4) , the Group earned 178.0 million euros, which equates to sales growth of 11.6%.
Business development of the divisions
The Bioprocess Solutions Division, which offers a wide array of innovative technologies for the manufacture of biopharmaceuticals, achieved sales growth of 20.9% (reported: +23.8%) to 326.0 million euros, compared to a moderate prior-year quarter. Strong demand across all product categories fueled this dynamic growth. Order intake also saw a significant uptick, rising 21.1% to 366.0 million euros.
Due to economies of scale and a change in accounting rules2) , the division’s underlying EBITDA rose by 34.0% to 94.2 million euros. The respective margin was 28.9%, up from 26.7% in the year-earlier period.
The Lab Products & Services Division, which offers products and technologies for laboratories primarily in the pharma sector and for life science research, developed in line with expectations. The division increased its sales relative to its previous year’s revenue base by 5.9% (reported: +8.1%) to 109.7 million euros. Order intake rose 4.4% against relatively high prior-year comparables to 116.8 million euros.
The division’s EBITDA increased 8.2%, totaling 19.8 million euros; its margin was 18.1%, approximately at the previous year’s level (Q1 2018: 18.0%). Earnings for this division were likewise positively affected by the change in accounting rules2) .
(All figures on sales revenue and order intake in constant currencies.)
Key financial indicators
The Sartorius Group continues to have a very sound balance sheet and financial base, even though its equity ratio decreased slightly from 38.5% at the end of 2018 to 36.8% mainly as a result of the change in accounting rules2) . The Group’s ratio of net debt to underlying EBITDA was 2.2 (Dec. 31, 2018: 2.4). After the first three months, the Group’s CAPEX ratio, i.e. ratio of capital expenditures to sales revenue, stood at 12.9% and is expected to decrease during the further course of the year after several large expansion projects are completed (previous year quarter: 10.3%)5) .
Guidance for the full year confirmed
Based on its first-quarter performance, Sartorius confirms its forecast for the full year of 2019. Consolidated sales revenue is thus projected to grow by about 7% to 11%. This forecast considers the changes to the sales alliance with the Lonza group in the area of cell culture media. Without these changes, sales growth would probably be some 2 percentage points higher. Regarding profitability, management forecasts that the company's EBITDA margin will increase to slightly more than 27.0% over the prior-year figure of 25.9%, with the operating gain projected to be about half a percentage point and the remaining increase expected to result from a change in accounting rules.2) The ratio of capital expenditures to sales revenue is projected to be around 12%, below the 2018 figure of 15.2%5) .
For the Bioprocess Solutions Division, management expects dynamic growth to continue. It anticipates that sales will increase by about 8% to 12% over the previous year’s high revenue base (without considering the modification of our partnership with Lonza, approx. 3 percentage points higher). Management forecasts that the division’s underlying EBITDA margin will increase to slightly more than 29.5% relative to the prior-year figure of 28.6%. The operating gain is expected to account for around half a percentage point.2)
The Lab Products & Services Division is partly dependent on the development of economic cycles. Against the backdrop of a weakened economy in many regions, management forecasts that the division’s sales revenue will increase by about 5% to 9% and the underlying EBITDA margin to slightly more than 20.0% (previous year: 18.5%), with the operating gain accounting for about half a percentage point2) .
All forecasts are based on constant currencies, as in the past years. A no-deal exit of the U.K. from the E.U. might impact our supply chains in both divisions to a certain degree in spite of the measures already taken to counteract this development. A reliable prognosis concerning possible effects cannot be made at the current time.
1) Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items) as the key profitability indicator.
2) IFRS 16 required to be applied as of 2019 regulates accounting of lease contracts. Ultimately, this leads to a somewhat extended balance sheet and thus to a slightly lower equity ratio. Further, the changes result in disclosure of longer-term lease payments as depreciation and, accordingly, in a somewhat higher EBITDA. This does not entail any material changes concerning the Group’s relevant net profit or earnings per share.
3) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects.
4) EMEA = Europe, Middle East, Africa
5) As of 2019, CAPEX is based on cash flow instead of balance sheet computation; CAPEX ratio restated: 11.1% for Q1 2018, 14.9% for FY 2018
This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.
Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn .
Conference call
Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, and Rainer Lehmann, CFO, will discuss the company's business results with analysts and investors on Thursday, April 18, 2019, at 3:30 p.m. Central European Summer Time (CEST) in a teleconference.
You may register by clicking on the following link:
http://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=6266464&linkSecurityString=2e6e97fe0
Alternatively, you can dial into the teleconference, without
registering, at:
+49 (0) 69 566 03 7000
The presentation will be available on Thursday, April 18, 2019, starting
at 3:15 p.m. CEST, for viewing on our website at:
https://www.sartorius.com/en/company/investor-relations/sartorius-ag-investor-relations/presentations
Current image files
https://www.sartorius.com/en/company/newsroom/downloads-publications
Financial calendar
July 19, 2019 | Publication of first-half figures (January to June 2019) | |
October 22, 2019 | Publication of nine-month figures (January to September 2019) | |
Key Performance Indicators for the First Quarter of 2019
Sartorius Group
|
Bioprocess Solutions |
Lab Products &
|
||||||||||||||||||||||||
In millions of € |
Q1
|
Q1 |
Δ in |
Δ in |
Q1
|
Q1 |
Δ in |
Δ in |
Q1
|
Q1 |
Δ in |
Δ in |
||||||||||||||
Sales Revenue and Order Intake | ||||||||||||||||||||||||||
Sales revenue | 435.7 | 364.9 | 19.4 | 16.8 | 326.0 | 263.4 | 23.8 | 20.9 | 109.7 | 101.4 | 8.1 | 5.9 | ||||||||||||||
- EMEA2) | 178.0 | 159.3 | 11.7 | 11.6 | 128.1 | 111.3 | 15.1 | 15.1 | 49.8 | 48.0 | 3.8 | 3.6 | ||||||||||||||
- Americas2) | 152.4 | 116.6 | 30.7 | 24.7 | 123.2 | 90.7 | 35.8 | 29.3 | 29.2 | 25.9 | 12.7 | 8.2 | ||||||||||||||
- Asia | |
105.3 | 89.0 | 18.4 | 15.3 | 74.7 | 61.5 | 21.6 | 18.7 | 30.6 | 27.5 | 11.3 | 7.8 | ||||||||||||||
Order intake | 482.8 | 404.8 | 19.3 | 16.6 | 366.0 | 295.1 | 24.0 | 21.1 | 116.8 | 109.6 | 6.6 | 4.4 | ||||||||||||||
EBITDA3) | 114.0 | 88.6 | 28.7 | 94.2 | 70.3 | 34.0 | 19.8 | 18.3 | 8.2 | |||||||||||||||||
EBITDA margin3)
|
26.2 | 24.3 | 28.9 | 26.7 | 18.1 | 18.0 | ||||||||||||||||||||
Net profit for |
48.6 | 37.2 | 30.8 | |||||||||||||||||||||||
Earnings per |
0.71 | 0.54 | 31.1 | |||||||||||||||||||||||
Earnings per |
0.72 | 0.55 | 30.5 | |||||||||||||||||||||||
1) | In constant currencies abbreviated as "cc" | |
2) | According to the customer's location | |
3) | Underlying | |
4) | After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects. | |
5) | A profile of Sartorius | |
The Sartorius Group is a leading international partner of biopharmaceutical research and the industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In fiscal 2018, the company earned sales revenue of some 1.57 billion euros. Currently, around 8,500 people work at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190417006060/en/
Contact:
Petra Kirchhoff | Head of Corporate Communications and Investor Relations +49 (0)551.308.1686 | petra.kirchhoff@sartorius.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting samarbejder med Mercurial Minds om at forbedre mulighederne inden for digital transformation4.7.2025 01:10:00 CEST | Pressemeddelelse
Andersen Consulting udvider sit udbud af teknologidrevne løsninger med tilføjelsen af samarbejdsfirmaet Mercurial Minds (M.M.), et konsulentfirma inden for digital transformation, AI og IT med base i Pakistan. M.M. blev grundlagt i 2013 og tilbyder en række tjenester, der er designet til at hjælpe organisationer med at udvikle sig og skalere, herunder i forbindelse med deres digitale transformationsstrategi, AI-tjenester, it-rådgivning og udvikling af robuste mobil- og webbrugeroplevelser. Firmaet leverer end-to-end-løsninger – udformning af datadrevne køreplaner, udvikling af intelligent automatisering og levering af sikre mobil- og weboplevelser, der kan skaleres – skræddersyet til virksomheder, der ønsker at forbedre sine forbindelsesmulighederne og opnå indsigter i realtid. M.M. betjener en bred vifte af brancher med fokus på finans, telekommunikation og andre dataintensive sektorer. "Dette samarbejde er en katalysator," siger Nabeel Saiyer, administrerende direktør for M.M. "Vores
Global Tourism Surging Ahead of Economic Growth, With Visits to Hit 30 Billion by 20344.7.2025 01:00:00 CEST | Press release
The World Economic Forum report, in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, predicts a significant uptick in tourist trips across the globeThe tourism sector will contribute $16 trillion to global GDP (more than 11% of the global economy) by 2034, according to World Travel & Tourism Council estimates (WTTC)India and China will be responsible for more than 25% of all outbound travel by 2030 The World Economic Forum has today published a new report forecasting that the travel and tourism industry is projected to serve 30 billion tourist trips by 2034. Travel and Tourism at a Turning Point: Principles for Transformative Growth, produced in collaboration with Kearney and the Ministry of Tourism Saudi Arabia, reveals a projected $16 trillion contribution to global GDP by the same year—representing more than 11% of the total world economy, according to World Travel & Tourism Council estimates. The report also found that the sector is expanding 1.5 times faster th
The 2025-2026 World Branding Awards Animalis Edition Honouring Leading Pet and Animal Brands Globally3.7.2025 21:00:00 CEST | Press release
The 2025-2026 World Branding Awards Animalis Edition marked its fifth instalment, bringing together leading pet and animal brands from all around the world. These brands were celebrated for their outstanding achievements, earning recognition as National, Regional, and Global Winners. The awards ceremony, held at Vienna's prestigious Hofburg Palace, welcomed winners across diverse categories, including pet food, retail, wellness, pet exhibitions, and aquatic products. Mounia Berrada-Gouzi expertly hosted the evening, which culminated in a grand celebration of brand excellence. “The Animalis Edition of the World Branding Awards recognises brands that have achieved the highest distinction—genuine recognition in the hearts and minds of consumers. Tonight, we honour those whose names resonate globally, whose values inspire loyalty, and whose presence defines excellence in the pet and animal industry,” said Richard Rowles, Chairman of the World Branding Forum. Out of over 950 brands nominate
Venture Global Announces 20-Year Sales and Purchase Agreement with PETRONAS3.7.2025 14:59:00 CEST | Press release
Today, Venture Global, Inc. (NYSE: VG) announced the execution of a new 20-year Sales and Purchase Agreement (SPA) with PETRONAS LNG Ltd. (PLL), a subsidiary of the Malaysian state-owned oil and gas company, PETRONAS. Under the terms of the SPA, PETRONAS will purchase 1 million tonnes per annum (MTPA) of liquefied natural gas (LNG) from Venture Global’s third facility, CP2 LNG, for 20 years. This builds upon Venture Global’s existing agreement with PETRONAS for 1 MTPA of LNG supply from Plaquemines LNG. PETRONAS, a world-class partner in the LNG industry, joins other CP2 LNG customers in Europe, Asia and the rest of the world in a strategically important project to global energy supply and security. To date, approximately 10.75 MTPA of the 14.4 MTPA nameplate capacity for CP2 Phase One has been sold. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets ac
Frost & Sullivan Recognizes Novotech as 2025 Global Biotech CRO Company of the Year3.7.2025 14:05:00 CEST | Press release
In recognition of its innovation, client-focused delivery, and global impact, Novotech has been awarded the 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year by Frost & Sullivan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250703950144/en/ Novotech Wins Global CRO Award Novotech is a globally recognized full-service clinical CRO and scientific advisory firm, trusted by biotech and small- to mid-sized pharmaceutical companies to advance their drug development programs at every phase. With a global footprint spanning Asia-Pacific, North America, and Europe, Novotech supports over 5,000 clinical trial sites and a distributed team of experts delivering seamless, end-to-end solutions across geographies. “Novotech is redefining biotech-focused clinical research through AI-driven innovation, global expansion, and a client-embedded partnership model. With a clear vision to be the CRO of choice for
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom